Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill creates non-binding House resolution expressing support for antiphospholipid syndrome (APS) testing as standard prenatal screening and calling on medical associations to update their clinical guidelines to include APS. The main policy areas are Healthcare and Finance.
Who Benefits and How
Pregnant women at risk for APS and pregnancy complications could face reduced risk and Clinical diagnostic laboratories offering prenatal testing could gain revenue opportunities.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Creates non-binding House resolution expressing support for antiphospholipid syndrome (APS) testing as standard prenatal screening and calling on medical associations to update their clinical guidelines to include APS...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates non-binding House resolution expressing support for antiphospholipid syndrome (APS) testing as standard prenatal screening and calling on medical associations to update their clinical guidelines to include APS.
Key Policy Areas
Healthcare, Finance
Primary Purpose
The bill creates non-binding House resolution expressing support for antiphospholipid syndrome (APS) testing as standard prenatal screening and calling on medical associations to update their clinical guidelines to include APS.
Policy Domains
Whole bill
Identified Gains
- Pregnant women at risk for APS and pregnancy complications
- Clinical diagnostic laboratories offering prenatal testing
Sponsors
Legislative Progress
In CommitteeMrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Clinical diagnostic laboratories offering prenatal testing
Professional medical associations (ACOG, SMFM, etc.)
Pregnant women at risk for APS and pregnancy complications
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology